Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ZARNESTRA, tipifarnib, R115777 · 3 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| ZARNESTRA, tipifarnib, R115777 | DRUG | - |
Inclusion Criteria: * Locally advanced, inoperable loco-regionally-recurrent, or metastatic breast cancer * Estrogen and/or progesterone positive disease * Progression of disease after antiestrogen therapy * Measurable disease * Postmenopausal * Eastern Cooperative Oncology Group (ECOG) performance...
ZARNESTRA, also known as tipifarnib or R115777, is an investigational small molecule being studied for the treatment of breast cancer, myelodysplastic syndrome, and acute myeloid leukemia. It is in Phase 2 clinical development for these oncology indications.
ZARNESTRA, also known as tipifarnib or R115777, is a small molecule that targets the enzyme farnesyltransferase. By inhibiting this enzyme, it interferes with the signaling pathways that cancer cells rely on for growth and survival.
ZARNESTRA, also known as tipifarnib or R115777, is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker symbol JNJ.
ZARNESTRA, also known as tipifarnib or R115777, is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA for any use. Clinical trials for breast cancer, myelodysplastic syndrome, and acute myeloid leukemia have been completed.
ZARNESTRA, also known as tipifarnib or R115777, has been studied in three completed Phase 2 trials. These include NCT00048503 for acute myeloid leukemia, NCT00050141 for advanced breast cancer, and NCT00050154 for high-risk myelodysplastic syndrome. All trials are completed.
Yes, ZARNESTRA is also known as tipifarnib and R115777. These names refer to the same investigational drug being developed by Johnson & Johnson for the treatment of certain cancers.